Why Ex-Dendreon CEO's New Startup Could Succeed Where Dendreon Failed

As former CEO of Seattle biotech Dendreon Corp. Mitchell Gold embarks on a new biotech immunotherapy company called Alpine Immune Sciences Inc., how will he ensure it doesn't meet the same fate as his prior company? Gold led Dendreon for nine years and stepped down in 2012. The Seattle cancer drug company is now bankrupt and recently sold its assets to Quebec-based Valeant Pharmaceuticals for $495 million.

Hey, check out all the research scientist jobs. Post your resume today!

Back to news